Showing 8051-8060 of 10214 results for "".
- Pinpointing BNP’s Role in ADhttps://practicaldermatology.com/news/pinpointing-bnps-role-in-ad/2462082/The brain natriuretic peptide (BNP) may play a role in activating atopic dermatitis, according to new research in mice. “BNP is expressed in sensory neurons, the neurons responsible for conveying sensation to the brain via the spinal cord,” says Santosh Mishra, associate pro
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Lebrikizumab Update: IL-13 Blocker Performs Well in AD Inadequately Controlled With Cyclosporinehttps://practicaldermatology.com/news/lebrikizumab-update-il-13-blocker-performs-well-in-ad-inadequately-controlled-with-cyclosporine/2462070/Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately controlled with cyclosporine or for whom cyclosporine was not medically adv
- Incyte and Mandy Moore Partner to Empower People with AD in New Campaignhttps://practicaldermatology.com/news/incyte-and-mandy-moore-partner-to-empower-people-with-ad-in-new-campaign/2462060/Actress, singer and songwriter Mandy Moore is partnering with Incyte on
- AbbVie’s JAK inhibitor RINVOQ "Measures Up" in ADhttps://practicaldermatology.com/news/abbvies-jak-inhibitor-rinvoq-measures-up-in-ad/2462057/New Phase 3 research supports the long-term efficacy and safety of RINVOQ (upadacitinib) in moderate to severe atopic dermatitis (AD), according to data analyses from the Measure Up 1, Measure Up 2, and AD Up studies presented at the European Academy of Dermatology and Venereology (EADV) Congress
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantl
- Drs. Jedd D. Wolchok and Lisa Newman Elected to National Academy of Medicinehttps://practicaldermatology.com/news/drs-jedd-d-wolchok-lisa-newman-elected-to-national-academy-of-medicine/2462055/Melanoma specialist Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, and Dr. Lisa Newman, chief of the section of breast surgery at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornel
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.